WHO announces start of Ebola vaccine clinical trial in DR Congo
0 / 15
English
中文
The World Health Organization (WHO) has announced the beginning of the first clinical trial of an Ebola vaccine in the outbreak that started in the Democratic Republic of Congo (DRC).
（暂无翻译）
WHO’s director-general, Tedros Adhanom Ghebreyesus, said in a social media post on Friday that participants in the trial were vaccinated with the Ervebo vaccine in Bunia, the capital of the DRC’s northeastern Ituri province, which is the epicentre of the Ebola outbreak.
（暂无翻译）
Ervebo, a vaccine approved for use against the more common Zaire strain of Ebola, will be put through a full-scale human trial to see if it offers any cross-protection against the Bundibugyo species of Ebola that is behind the epidemic.
（暂无翻译）
“This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work,” the WHO chief said on X.
（暂无翻译）
“WHO is supporting this DRC-led effort to find answers and save lives,” he added.
（暂无翻译）
The DRC declared its 17th and worst-ever Ebola outbreak in May and has since reported more than 9,700 cases, with the number of deaths exceeding 4,600.
（暂无翻译）
The WHO, in response, triggered a public health emergency of international concern, its second-highest alert level.
（暂无翻译）
The current outbreak has now been reported in four countries across eastern, central and western Africa, giving it the widest geographic spread of any Ebola outbreak on the continent to date.
（暂无翻译）
The so-called Tumaini trial is a single trial framework that can test the safety, efficacy and immunogenicity of multiple vaccines.
（暂无翻译）
The trial will use a ring vaccination approach: immunising contacts deemed to be at high risk of infection.
（暂无翻译）
The trial is set to incorporate two Bundibugyo-specific candidate vaccines, which are currently advancing through earlier-stage, smaller-scale clinical trials.
（暂无翻译）
One is a ChAdOx1 adenoviral vector jab being developed by the University of Oxford; the other, by the US-based Moderna group, uses mRNA technology.
（暂无翻译）
Both have received funding from the Coalition for Epidemic Preparedness Innovations and are expected to enter the trial “shortly”, CEPI said in a statement.
（暂无翻译）
The trial will include pregnant women and children aged 12 years and older, generating evidence for populations that are often excluded from clinical trials.
（暂无翻译）
WHO emergencies director Chikwe Ihekweazu said the trial was set up to generate the rigorous evidence needed to determine whether the participating vaccines could protect people at risk.
（暂无翻译）
仅供学习使用，如有侵权请联系删除 · 查看原文